blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2997976

EP2997976 - METHODS AND COMPOSITIONS FOR INCREASING ALPHA-L-IDURONIDASE ACTIVITY IN THE CNS [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  21.02.2020
Database last updated on 20.09.2024
FormerExamination is in progress
Status updated on  15.09.2017
Most recent event   Tooltip21.02.2020Refusal of applicationpublished on 25.03.2020  [2020/13]
Applicant(s)For all designated states
Armagen, Inc.
30301 Agoura Road No.110
Agoura Hills, CA 91301 / US
[2019/09]
Former [2017/47]For all designated states
Armagen, Inc.
26679 Agoura Road, No.100
Calabasas, CA 91302 / US
Former [2016/12]For all designated states
ArmaGen Technologies, Inc.
914 Colorado Avenue
Santa Monica, CA 90401 / US
Inventor(s)01 / PARDRIDGE, William
1180 Tellem Drive
Pacific Palisades, CA 90272 / US
02 / BOADO, Ruben
29211 Trailway Lane
Agoura Hills, CA 91301 / US
 [2016/12]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2016/12]Kremer, Simon Mark, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date15175407.425.07.2008
[2016/12]
Priority number, dateUS20070952547P27.07.2007         Original published format: US 952547 P
[2016/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2997976
Date:23.03.2016
Language:EN
[2016/12]
Search report(s)(Supplementary) European search report - dispatched on:EP19.02.2016
ClassificationIPC:A61K39/00, C07K16/28, C07K16/40, C07K16/46, C12N9/00
[2016/12]
CPC:
C07K16/40 (EP,US); C07K19/00 (US); A61K47/6849 (EP,US);
A61K9/0019 (US); A61P25/00 (EP); A61P25/28 (EP);
A61P43/00 (EP); C07K16/2869 (EP,US); C07K16/46 (EP,US);
C12N9/0002 (EP,US); C12N9/2402 (EP,US); C12Y302/01076 (EP,US);
A61K2039/505 (EP,US); A61K38/00 (EP,US); A61K47/6801 (EP,US);
A61K47/6815 (EP,US); A61K47/6843 (EP,US); C07K2317/24 (EP,US);
C07K2317/51 (US); C07K2317/515 (US); C07K2317/55 (US);
C07K2317/565 (US); C07K2317/622 (US); C07K2317/92 (EP,US);
C07K2317/94 (US); C07K2319/00 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/12]
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR ERHÖHUNG DER ALPHA-IDURONIDASE-AKTIVITÄT IM ZNS[2016/12]
English:METHODS AND COMPOSITIONS FOR INCREASING ALPHA-L-IDURONIDASE ACTIVITY IN THE CNS[2016/12]
French:PROCÉDÉS ET COMPOSITIONS POUR AUGMENTER L'ACTIVITÉ ALPHA-L-IDURONIDASE DANS LE SYSTÈME NERVEUX CENTRAL[2016/12]
Examination procedure24.07.2015Examination requested  [2016/12]
31.10.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
10.01.2017Amendment by applicant (claims and/or description)
15.09.2017Despatch of a communication from the examining division (Time limit: M06)
23.03.2018Reply to a communication from the examining division
12.09.2019Application refused, date of legal effect [2020/13]
12.09.2019Date of oral proceedings
25.10.2019Minutes of oral proceedings despatched
07.11.2019Despatch of communication that the application is refused, reason: substantive examination [2020/13]
Parent application(s)   TooltipEP08796594.3  / EP2182980
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
10.01.2017Request for further processing filed
10.01.2017Full payment received (date of receipt of payment)
Request granted
30.01.2017Decision despatched
Fees paidRenewal fee
24.07.2015Renewal fee patent year 03
24.07.2015Renewal fee patent year 04
24.07.2015Renewal fee patent year 05
24.07.2015Renewal fee patent year 06
24.07.2015Renewal fee patent year 07
24.07.2015Renewal fee patent year 08
27.07.2016Renewal fee patent year 09
27.07.2017Renewal fee patent year 10
27.07.2018Renewal fee patent year 11
29.07.2019Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]US5527527  (FRIDEN PHILLIP M [US]) [Y] 1-16 * The whole document, in particular the examples *;
 [XY]WO2004050016  (UNIV CALIFORNIA [US], et al) [X] 1-16 * The whole document, in particular:;; figures 1,4,5; example 6 * [Y] 1-16;
 [Y]US6858206  (KAKKIS EMIL D [US]) [Y] 1-16 * The whole document, in particular the examples *;
 [IY]US2005142141  (PARDRIDGE WILLIAM M [US]) [I] 1-16 * The whole document, in particular examples 6-7 * [Y] 1-16;
 [I]  - SCHLACHETZKI FELIX ET AL, "Gene therapy of the brain - The trans-vascular approach", NEUROLOGY, (20040427), vol. 62, no. 8, ISSN 0028-3878, pages 1275 - 1281, XP009156992 [I] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1212/01.WNL.0000120551.38463.D9
 [A]  - SIFUENTES ET AL, "A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years", MOLECULAR GENETICS AND METABOLISM, ACADEMIC PRESS, SAN DIEGO, CA, US, (20070119), vol. 90, no. 2, doi:10.1016/J.YMGME.2006.08.007, ISSN 1096-7192, pages 171 - 180, XP005735911 [A] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ymgme.2006.08.007
 [XP]  - RUBEN J. BOADO ET AL, "Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier", BIOTECHNOLOGY AND BIOENGINEERING, (20080201), vol. 99, no. 2, doi:10.1002/bit.21602, ISSN 0006-3592, pages 475 - 484, XP055020493 [XP] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1002/bit.21602
 [A]  - RUDIKOFF S ET AL, "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC; US, (19820301), vol. 79, doi:10.1073/PNAS.79.6.1979, ISSN 0027-8424, pages 1979 - 1983, XP007901436 [A] 11,12 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.79.6.1979
 [T]  - RUBEN J. BOADO ET AL, "Reversal of Lysosomal Storage in Brain of Adult MPS-I Mice with Intravenous Trojan Horse-Iduronidase Fusion Protein", MOLECULAR PHARMACEUTICS, (20110801), vol. 8, no. 4, doi:10.1021/mp200136x, ISSN 1543-8384, pages 1342 - 1350, XP055020504 [T] * the whole document *

DOI:   http://dx.doi.org/10.1021/mp200136x
 [T]  - RUBEN J. BOADO ET AL, "AGT-181: Expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys", JOURNAL OF BIOTECHNOLOGY, (20091001), vol. 144, no. 2, doi:10.1016/j.jbiotec.2009.08.019, ISSN 0168-1656, pages 135 - 141, XP055020498 [T] * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jbiotec.2009.08.019
 [A]  - PARDRIDGE W M, "Blood-Brain Barrier Drug Targeting: The Future of Brain Drug Development", MOLECULAR INTERVENTIONS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, BETHESDA,MD, US, (20030301), vol. 3, no. 2, doi:10.1124/MI.3.2.90, ISSN 1534-0384, pages 90 - 105, XP002993086 [A] 1 * the whole document *

DOI:   http://dx.doi.org/10.1124/mi.3.2.90
 [A]  - MCGRATH J P ET AL, "Bifunctional fusion between nerve growth factor and a transferrin receptor antibody", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, (19970101), vol. 47, ISSN 0360-4012, pages 123 - 133, XP002698610 [A] 1 * the whole document *

DOI:   http://dx.doi.org/10.1002/(SICI)1097-4547(19970115)47:2<123::AID-JNR1>3.0.CO;2-H
 [T]  - BOADO RUBEN J ET AL, "Genetic engineering of IgG-glucuronidase fusion proteins", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, (20100401), vol. 18, no. 3, doi:10.3109/10611860903353362, ISSN 1061-186X, pages 205 - 211, XP009171492 [T] * the whole document *

DOI:   http://dx.doi.org/10.3109/10611860903353362
 [A]  - HAISMA HJ ET AL, "Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (19980701), ISSN 0006-4971, XP002076505 [A] 1 * the whole document *
 [A]  - MAHLER H C ET AL, "Induction and analysis of aggregates in a liquid IgG1-antibody formulation", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 59, no. 3, ISSN 0939-6411, (20050401), pages 407 - 417, (20050401), XP027805032 [A] 1 * the whole document *
by applicantUS5527288
 US5656284
 US5848991
 US5997501
 US6041775
 US6060069
 US6284262
 US6322808
 US6348210
 US6361760
 US6375975
 US2004101904
 US2005142141
    - BATZER ET AL., NUCLEIC ACID RES., (1991), vol. 19, page 5081
    - OHTSUKA ET AL., J BIOL. CHEM., (1985), vol. 260, pages 2605 - 2608
    - ROSSOLINI ET AL., MOL. CELL. PROBES, (1994), vol. 8, pages 91 - 98
    - YIP, J BIOI. CHEM, (2003), vol. 278, no. 30, pages 27329 - 27332
    - WHITTAKER ET AL., JBIOL CHEM, (2005), vol. 280, no. 22, pages 20932 - 20936
    - KABAT ET AL., Sequences of Proteins of Immunological Interest, 5th ed., PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH, BETHESDA, MD., (1991), pages 647 - 669
    - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - HOLLIGER ET AL., NATURE BIOTECH., (2005), vol. 23, no. 9, pages 1126 - 1129
    - WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546
    - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883
    - OSBOURN ET AL., NAT. BIOTECHNOL., (1998), vol. 16, page 778
    - PLUCKTHUN, PLUCKTHUN, ROSENBURG AND MOORE, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
    - BOADO ET AL., BIOTECHNOL BIOENG, (2007), vol. 96, no. 2, pages 381 - 391
    - FUKUDA ET AL., "In vitro evolution of single-chain antibodies using mRNA display", NUC. ACID RES., (2006), vol. 34, no. 19, doi:doi:10.1093/NAR/GKL618, XP002639193

DOI:   http://dx.doi.org/10.1093/NAR/GKL618
    - CHEN ET AL., "In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site", PROT ENG, (1999), vol. 12, no. 4, pages 349 - 356, XP003001853
    - COLOMA ET AL., PHARM RES, (2000), vol. 17, pages 266 - 274
    - REMPEL ET AL., "A homology model for human a-L-Iduronidase: Insights into human disease", MOL. GENETICS AND MET., (2005), vol. 85, doi:doi:10.1016/j.ymgme.2004.12.006, pages 28 - 37, XP027447084

DOI:   http://dx.doi.org/10.1016/j.ymgme.2004.12.006
    - HENIKOFF ET AL., "Predicting the Effects of Amino Acid Substitutions on Protein Function", ANNU. REV. GENOMICS HUM. GENET., (2006), vol. 7, doi:doi:10.1146/annurev.genom.7.080505.115630, pages 61 - 80, XP055415263

DOI:   http://dx.doi.org/10.1146/annurev.genom.7.080505.115630
    - KAKKIS ET AL., PROT EXPR PURIF, (1994), vol. 5, pages 225 - 232
    - ALTSCHUL ET AL., BULL. MATH. BIO., (1986), vol. 48, page 603
    - HENIKOFF; HENIKOFF, PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, page 10915
    - PEARSON; LIPMAN, PROC. NAT'L ACAD. SCI. USA, (1988), vol. 85, page 2444
    - PEARSON, METH. ENZYMOL., (1990), vol. 183, page 63
    - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 444
    - SELLERS, SIAM J. APPL. MATH., (1974), vol. 26, page 787
    - HENIKOFFAND HENIKOFF, PROC. NAT'L ACAD. SCI. USA, (1992), vol. 89, page 10915
    - BOADO ET AL., BIOTECHNOL BIOENG, (2007), vol. 96, pages 381 - 391
    - HE ET AL., MOL GENET METAB, (1999), vol. 67, pages 106 - 112
    - KAKKIS, PROT EXPR PURIF, (1994), vol. 5, pages 225 - 232
    - ZHANG ET AL., HUM GENE THER, (2004), vol. 15, pages 339 - 350
    - TRIGUERO ET AL., J NEUROCHEM, (1990), vol. 54, pages 1882 - 1888
    - PARDRIDGE ET AL., PHARM RES, (1995), vol. 12, pages 807 - 816
    - COLOMA ET AL., PHARMA RES, (2000), vol. 17, pages 266 - 274
    - CROW ET AL., J CLIN PATHOL, (1983), vol. 36, pages 415 - 430
 US20050061956
 US20050245710
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.